Kriya Therapeutics, a US-based developer of gene therapies based on research at Stanford University, closed a $100m series B round on Wednesday that included pharmaceutical firm Dexcel Pharma.
The round was led by investment firm Patient Square Capital and also featured QVT Financial, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo, JDRF T1D Fund, Woodline Partners, CAM Capital, Hongkou Capital, Alumni Ventures and unnamed others.
Founded in 2019, Kriya is working on a fully integrated platform designed to reduce the time it takes a gene therapy to get to market and the cost per dose.
The company initially focused on type 1 and type 2 diabetes as well as severe obesity, but has built a diversified pipeline of assets, covering rare and prevalent metabolic, ophthalmic and oncologic diseases.
The funding is being allocated to further platform development and will also allow Kriya to expand its pipeline and progress existing drug candidates. Jim Momtazee, managing partner of Patient Square Capital, will join its board of directors.
Kriya had previously raised $80.5m in a May 2020 series A round backed by Dexcel Pharma, QVT Financial, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Asia Alpha, Paul Manning and Transhuman Capital, which had supplied an undisclosed amount of seed funding at the time of its launch.
The original version of this article appeared on our sister site, Global University Venturing.
